A study found combining trastuzumab biosimilar HLX02, pertuzumab, and chemotherapy was effective and safe for patients with HER2-positive metastatic breast cancer who progressed after prior trastuzumab therapy.
A combination of trastuzumab biosimilar HLX02, pertuzumab, and chemotherapy exhibited efficacy and favorable safety as second and beyond line therapy in patients with HER2-positive metastatic breast cancer.
From March 2020 to December 2021, a Beijing Cancer Hospital held a prospective, single-arm, single-center, phase 2 clinical trial. Eligible participants included patients diagnosed with metastatic breast cancer who were previously treated with trastuzumab alone but experienced disease progression during or after therapy.
Based on the physician, patients were assigned trastuzumab (HLX02), pertuzumab and chemotherapy at baseline. Trastuzumab (HLX02) was administered intravenously as an 8 mg/kg loading dose followed by 6 mg/kg maintenance doses every 3 weeks. Pertuzumab was administered intravenously as an 840 mg loading dose followed by 420 mg maintenance doses every 3 weeks.
Every 6 weeks, tumor assessment was computed with a tomography scan of the chest and if the disease progressed after 6 months, the investigator made the decision on whether to continue chemotherapy or not. Trastuzumab and pertuzumab continued to be administered until disease progressed or toxicity became intolerable to patients.
Study results found treatment was well tolerated among participants. A total of 45 patients were included in the data with a median age of 56 years. Of the total number of patients, 12 (26.7%) were treated in second line, while 33 (73.3%) were treated in third line and later settings.
The primary endpoint of the study was the progression free survival (PFS), which was calculated from the time of first administration to the time of disease progression or death. Follow-up consisted of an average of 24.4 months, with 35 of the 45 patients enduring PFS events for about 7.6 months. There were no major differences observed in the subgroup analysis for PFS.
Overall survival, a secondary endpoint of the study calculating the time of the first administration to the time of death due to any cause, was unable to be reached due to the short follow-up period.
Another secondary endpoint of the study, objective response rate (ORR), was defined as the proportion of patients with measurable disease whose best overall response was evaluated as either complete remission (CR) or partial remission (PR). At the end of the study, 14 (31.1%) patients achieved PR, 27 (60%) had stable disease, and 4 (8.9%) had progressive disease. None of the patients had a CR.
Lastly, the disease control rate (DCR) was a secondary endpoint defined as the proportion of patients who achieved CR, PR, and stable disease (SD). Patients achieved a 31.1% ORR with a 91.1% DCR.
The safety profile of the treatments found most toxicities were grade 1 or 2 and manageable. The most common adverse events were neutropenia (n = 20 patients; 44%), anemia (n = 9; 20%), diarrhea (n = 9; 20%), and alanine aminotransferase/aspartate aminotransferase elevation (n = 8; 17.8%).
Adverse events graded a 3 or higher, mainly neutropenia patients (n = 3; 6.7%), were ruled to mainly be associated with chemotherapy instead of trastuzumab or pertuzumab. Overall, the study regimen did not exhibit any unexpected toxicities.
The study's main limitation was the single arm, single center study design. Additionally, the follow-up period was not long enough to allow for an overall survival analysis.
Authors concluded that their findings provide new evidence for treatment of dual-antibody therapy in late-line settings of patients with HER2-positive metastatic breast cancer.
Reference
Zhang R, Liu X, Song G, Zhang Y, Li H. Trastuzumab biosimilar (HLX02), pertuzumab plus chemotherapy in patients with HER2-positive metastatic breast cancer after progression of trastuzumab: A prospective, phase II study. Cancer Res Treat. Published online December 20, 2023. doi:10.4143/crt.2023.1151
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Achieving PFS in Advanced Gastric Cancer With HLX02 Biosimilar, Chemotherapy
November 23rd 2024In a phase 2 study, the addition of HLX22, an anti-HER2 antibody, to HLX02 biosimilar and XELOX (oxaliplatin and capecitabine) chemotherapy extended progression-free survival (PFS) in untreated HER2-positive advanced gastric cancer patients.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.
Samsung Bioepis Report Showcases Adalimumab Biosimilar Growth in Market Share
October 11th 2024Adalimumab biosimilars have seen a significant increase in market share, from 2% in early 2024 to 22%, as payers and pharmacy benefit managers begin to prioritize these biosimilars over the reference product, Humira.